New technique for endothelial grafts

Article

Looking at a new technique to prepare and transplant endothelial grafts usinf subendothelial air injections to separate donor Descemet and endothelium from overlying stroma.

Key Points

For this reason Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) was developed and in recent years it has gained widespread popularity. With this procedure the recipient cornea is maintained, with the exception of the complex Descemet membrane and endothelium, which are removed from the central part (usually 9 mm in diameter) of the posterior corneal surface. The donor graft consists of a thin lamella (usually between 100 µm and 200 µm in thickness) of deep stroma carrying the donor Descemet membrane and endothelium and is attached to the recipient cornea by means of an air bubble. Although cornea clarity is re-established by DSAEK in a relatively short period of time, the resulting stromal interface is considered by some authors a limiting factor for final visual acuity (VA).

From DSAEK to DMEK

Technical obstacles

To date, several technical problems relating to Dr Melles's technique have limited the popularity of DMEK among corneal surgeons. In particular, waste of donor tissue when detaching Descemet from overlying stroma should be avoided, while manipulation of donor tissue during delivery and positioning should be minimized.

First steps

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Alexandra Miere, MD, PhD, Associate Professor of Ophthalmology, University Paris Est Créteil, France, speaks at EURETINA
Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.
© 2024 MJH Life Sciences

All rights reserved.